Longitudinal Analysis of the Intestinal Microbiota in Liver Transplantation

Background Increasing evidence suggests that the intestinal microbiota plays an important role in liver diseases. However, the dynamics of the intestinal microbiota during liver transplantation (LT) and its potential role in clinical course remain unknown. Methods We prospectively analyzed the intestinal microbiota of 38 patients who underwent LT in Kyoto University Hospital. We characterized the microbial compositions of fecal specimens from LT patients using a metagenomics approach by an Illumina MiSeq platform. We analyzed the diversity of microbiota sequentially from pretransplantation until 2 months after LT and also compared the microbiota during an episode of acute cellular rejection (ACR) and bloodstream infections (BSI) to the microbial composition of time-matched fecal specimens obtained from patients who did not experience ACR or BSI, respectively. Results Three hundred twenty fecal specimens were analyzed. Dynamic changes were observed in the microbial composition of LT recipients during the perioperative period. Over the course of LT, the mean diversity index decreased during the first 3 weeks after LT and gradually increased during our observation period. The loss of intestinal microbiota diversity was associated with high Child-Pugh scores, high model for end-stage liver disease scores, ACR, and BSI. At the family level, Bacteroides, Enterobacteriaceae, Streptococcaceae, and Bifidobacteriaceae were increased whereas Enterococcaceae, Lactobacillaceae, Clostridiaceae, Ruminococcaceae, and Peptostreptococcaceae were decreased in ACR patients. Conclusions The microbiota of LT patients was associated with the severity of liver diseases and the presence of ACR and BSI. These results lay the groundwork for more comprehensive investigations of microbiota characteristics to identify diagnostic markers for transplant health and to guide intervention strategies to improve transplant outcomes.

[1]  Brian Goodman,et al.  The microbiome and cancer , 2018, The Journal of pathology.

[2]  P. Hylemon,et al.  Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis , 2016, Scientific Reports.

[3]  S. Ichiyama,et al.  Epidemiology of invasive fungal infections after liver transplantation and the risk factors of late-onset invasive aspergillosis. , 2016, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[4]  D. Brenner,et al.  Role of Gut Microbiota in Liver Disease. , 2015, Journal of clinical gastroenterology.

[5]  R. Jalan,et al.  Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis , 2015, The American Journal of Gastroenterology.

[6]  E. Le Chatelier,et al.  Qin et al. reply , 2015, Nature.

[7]  S. Ichiyama,et al.  Changes in Surgical Site Infections after Living Donor Liver Transplantation , 2015, PloS one.

[8]  Weilin Wang,et al.  Gut microbiota and allogeneic transplantation , 2015, Journal of Translational Medicine.

[9]  C. Surawicz,et al.  The gut microbiome: a clinically significant player in transplantation? , 2015, Expert review of clinical immunology.

[10]  E. Mongodin,et al.  Microbiota—implications for immunity and transplantation , 2015, Nature Reviews Nephrology.

[11]  Depei Wu,et al.  The Role of Intestinal Microbiota in Acute Graft-versus-Host Disease , 2015, Journal of immunology research.

[12]  G. Reid,et al.  Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases. , 2015, Inflammation & allergy drug targets.

[13]  Nora C. Toussaint,et al.  Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation , 2015, PloS one.

[14]  S. Uemoto,et al.  Perioperative nutritional therapy in liver transplantation , 2015, Surgery Today.

[15]  S. Uemoto,et al.  Perioperative changes in nutritional parameters and impact of graft size in patients undergoing adult living donor liver transplantation , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[16]  Weilin Wang,et al.  Intestinal Microbial Variation May Predict Early Acute Rejection after Liver Transplantation in Rats , 2014, Transplantation.

[17]  Nora C. Toussaint,et al.  Gut Microbial Community Structure and Complications After Kidney Transplantation: A Pilot Study , 2014, Transplantation.

[18]  M. Krawczyk,et al.  Gut microbiota in cirrhotic liver transplant candidates. , 2014, Hepato-gastroenterology.

[19]  Beiwen Zheng,et al.  Alterations of the human gut microbiome in liver cirrhosis , 2014, Nature.

[20]  W. F. Fricke,et al.  Human Microbiota Characterization in the Course of Renal Transplantation , 2014, American Journal of Transplantation.

[21]  B. Chassaing,et al.  Microbiota‐liver axis in hepatic disease , 2014, Hepatology.

[22]  K Ogawa,et al.  Impact of Sarcopenia on Survival in Patients Undergoing Living Donor Liver Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  H. Nittono,et al.  Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. , 2013, Journal of hepatology.

[24]  N. Socci,et al.  Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  A. Klindworth,et al.  Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies , 2012, Nucleic acids research.

[26]  Raul Rabadan,et al.  Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. , 2012, Cancer cell.

[27]  L. Tang,et al.  Comparison of the Gut Microbe Profiles and Numbers Between Patients with Liver Cirrhosis and Healthy Individuals , 2012, Current Microbiology.

[28]  Rob Knight,et al.  Using QIIME to Analyze 16S rRNA Gene Sequences from Microbial Communities , 2011, Current protocols in bioinformatics.

[29]  S. Uemoto,et al.  Management of ABO-incompatible living-donor liver transplantation: Past and present trends , 2011, Surgery Today.

[30]  G. Cao,et al.  Endotoxin accumulation prevents carcinogen‐induced apoptosis and promotes liver tumorigenesis in rodents , 2010, Hepatology.

[31]  Y. Maetani,et al.  Living donor liver transplantation as a second‐line therapeutic strategy for patients with hepatocellular carcinoma , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[32]  R. Ley,et al.  Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine , 2006, Cell.

[33]  E. Purdom,et al.  Diversity of the Human Intestinal Microbial Flora , 2005, Science.

[34]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[35]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[36]  K. Watt,et al.  The Intestinal Microbiome and the Liver Transplant Recipient: What We Know and What We Need to Know. , 2016, Transplantation.